Novel immunotherapies for tuberculosis and other mycobacterial diseases - ITHEMYC

结核病和其他分枝杆菌疾病的新型免疫疗法 - ITHEMYC

• 批准号: 10084672
• 金额: $ 137.29万
• 依托单位: DEPARTMENT OF HEALTH AND SOCIAL CARE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10084672
• 关键词: Novel; immunotherapies; tuberculosis; other; mycobacterial

Tuberculosis (TB) remains the leading cause of death due to a single pathogen, Mycobacterium tuberculosis (Mtb; except in 2020-2022, when it was surpassed by the COVID-19 pandemic), with 1.5 million deaths in 2020. The lengthy TB treatment and the numerous adverse events contribute to poor medical adherence and development of antibiotic resistant strains. Thus, novel therapeutic modalities are urgently needed to shorten treatment duration, improve outcomes and control the emergence of drug resistant TB. The ITHEMYC project convenes a multidisciplinary consortium of 11 partners, including two Product Development Partnerships (TBVI, TB-Alliance) and an industrial partner (GSK) involved in vaccine, drug and biomarker R&D for TB. The partners will work jointly to develop innovative adjunctive TB immunotherapies by capitalizing on a promising pipeline and recent developments in the field. The project will combine current and new antibiotic regimens with novel immunotherapies,such assmall moleculestargeting host pathogen-interactions, including host-directed therapies and virulence inhibitors, immunomodulatory compounds, monoclonal antibodies and therapeutic vaccines. The project will generate robust preclinical safety and efficacy information on compounds and combinations through a set of relevant in vitro, in vivo and in silico models, and progress two of them up to preclinical proof-of-concept in non-human primates within the project duration. The partners are proposing a critical path for characterization and progression of immunotherapies, that will be refined based on knowledge generated in ITHEMYC aiming to increase the understanding and interest for this emerging concept of adjunctive TB immunotherapy. We expect the new combined interventions will improve TB cure rates, reduce the duration and toxicity of current regimens and reduce relapse rates.

结核病仍然是由单一病原体结核分枝杆菌（Mtb；除了2020-2022年被COVID-19大流行超越之外）造成的主要死亡原因，2020年死亡人数为150万人。漫长的结核病治疗和众多不良事件导致医疗依从性差和抗生素耐药菌株的发展。因此，迫切需要新的治疗方式来缩短治疗时间，改善结果并控制耐药结核病的出现。ITHEMYC项目召集了一个由11个合作伙伴组成的多学科联盟，包括两个产品开发合作伙伴（TBVI，结核病联盟）和一个参与结核病疫苗、药物和生物标志物研发的工业合作伙伴（GSK）。合作伙伴将共同开发创新的结核病辅助免疫疗法，利用有前景的药物管线和该领域的最新发展。该项目将结合当前和新的抗生素方案与新的免疫疗法，如小分子靶向宿主病原体相互作用，包括宿主定向疗法和毒力抑制剂、免疫调节化合物、单克隆抗体和治疗性疫苗。该项目将通过一系列相关的体外、体内和计算机模型，生成有关化合物和组合的可靠的临床前安全性和有效性信息，并在项目期间将其中两种方法推进到非人类灵长类动物的临床前概念验证。合作伙伴正在提出免疫疗法表征和进展的关键途径，该途径将根据ITHEMYC中产生的知识进行完善，旨在增加对辅助结核病免疫治疗这一新兴概念的理解和兴趣。我们期望新的联合干预措施将提高结核病治愈率，缩短当前治疗方案的持续时间和毒性，并降低复发率。